Author

Sundar Jagannath

Tisch Cancer InstituteORCID 0000-0003-2934-6518Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Genetic & Genomic Medicine· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:differential expression· 2 Organism:human· 2 Approach:statistical model· 2 Research Focus:clustering· 1 Assay:whole-exome sequencing· 1 Assay:whole-genome sequencing· 1

Frequent Co-Authors

Ajai ChariiD· 2 shared Hearn Jay ChoiD· 2 shared Adolfo AlemaniD· 1 shared Adrienne HellandiD· 1 shared Ahmet A. Kurdoglu· 1 shared Alessandro LaganàiD· 1 shared Alex Blanski· 1 shared Andrea Donnelly· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersGenetic & Genomic Medicine

Ajai ChariORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Genetic & Genomic MedicineJCO Precision OncologyPeer-reviewedJun 1, 2022

A three gene signature predicts response to selinexor in multiple myeloma

Paula Restrepo, Sherry Bhalla, Yogita Ghodke‐Puranik…·Samir Sunil Parekh

The paper identifies a three-gene expression signature that predicts response to selinexor in multiple myeloma and glioblastoma.

18 citations

humanbulk RNA-seq

𝕏 PostBluesky

Genetic & Genomic MedicinemedRxivPreprintAug 2, 2021

Genomic Basis of Multiple Myeloma Subtypes from the MMRF CoMMpass Study

Sheri Skerget, Daniel Peñaherrera, Ajai Chari…·Jonathan J. Keats

The paper identifies genomic subtypes of multiple myeloma using the MMRF CoMMpass study and finds that 25.5% of patients transition to a high-risk expression subtype at progression, which expresses immunotherapy targets.

19 citations

humanwhole-exome sequencing

𝕏 PostBluesky